Fluidda

Company profile

About Fluidda

Fluidda is the world leader in Functional Respiratory Imaging (FRI), a pioneering technology that combines high-resolution CT scans with Computational Fluid Dynamics (CFD) and artificial intelligence to revolutionize respiratory healthcare. Founded in 2005 and headquartered in Kontich, Belgium, Fluidda applies advanced engineering tools originally developed for aerospace applications to improve the diagnosis, monitoring, and treatment of respiratory diseases. The company operates as both a Contract Research Organization (CRO) providing services to pharmaceutical and biotech companies, and as a partner to healthcare professionals offering clinical decision support. Fluidda's FRI technology enables patient-specific analysis of lung structure and function, providing regional information that traditional lung function tests cannot capture. This approach makes clinical trials shorter, faster, and more cost-effective while enabling personalized medicine through optimized diagnosis and treatment monitoring. Fluidda's proprietary technology platform includes advanced algorithms for measuring blood vessel wall thickness, airway geometry, airflow distribution, and vascular density from standard CT scans. The company's Broncholab product assists radiologists and pulmonologists with treatment optimization for respiratory patients. In November 2025, Fluidda was acquired by Banook, a global leader in clinical trial services, strengthening its position in respiratory clinical research. Fluidda serves customers across pharmaceutical companies, medical device manufacturers, healthcare systems, and research institutions worldwide, with offices in Belgium, the United States (New York and Los Angeles), and Portugal (Lisbon).

Company description · Fluidda official website